Eintrag weiter verarbeiten
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer
Gespeichert in:
| Zeitschriftentitel: | Cancer Prevention Research |
|---|---|
| Personen und Körperschaften: | , , , , , , , , , |
| In: | Cancer Prevention Research, 5, 2012, 11_Supplement, S. A19-A19 |
| Format: | E-Article |
| Sprache: | Englisch |
| veröffentlicht: |
American Association for Cancer Research (AACR)
|
| Schlagwörter: |
| author_facet |
Liu, Mei Wu, Lingying Xu, Ningzhi An, Jusheng Hu, Jinlong Huang, Manni Tu, Binbin Hu, Chenfei Wang, Zaozao Zhu, Hongxia Liu, Mei Wu, Lingying Xu, Ningzhi An, Jusheng Hu, Jinlong Huang, Manni Tu, Binbin Hu, Chenfei Wang, Zaozao Zhu, Hongxia |
|---|---|
| author |
Liu, Mei Wu, Lingying Xu, Ningzhi An, Jusheng Hu, Jinlong Huang, Manni Tu, Binbin Hu, Chenfei Wang, Zaozao Zhu, Hongxia |
| spellingShingle |
Liu, Mei Wu, Lingying Xu, Ningzhi An, Jusheng Hu, Jinlong Huang, Manni Tu, Binbin Hu, Chenfei Wang, Zaozao Zhu, Hongxia Cancer Prevention Research Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer Cancer Research Oncology |
| author_sort |
liu, mei |
| spelling |
Liu, Mei Wu, Lingying Xu, Ningzhi An, Jusheng Hu, Jinlong Huang, Manni Tu, Binbin Hu, Chenfei Wang, Zaozao Zhu, Hongxia 1940-6207 1940-6215 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1940-6207.prev-12-a19 <jats:title>Abstract</jats:title> <jats:p>Cervical cancer is one of the most common cancers in women worldwide. Advanced uterine cervical squamous cell carcinomasuterine (UCSCC) patients in FIGO stage IIb or IIIb treated with platinum based concomitant chemoradiotherapy. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in UCSCC. In this study, we identified the relationship between miR-19a and sensitivity to concomitant chemoradiotherapy. The UCSCC patients in FIGO stage IIb or IIIb treated with platinum based concurrent chemoradiotherapy at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Patients with progressive disease during first line platinum based chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patients without recurrence or with recurrences beyond 6 months were termed sensitive. We examined the expression level of miR-19a in 30 cervix biopsies samples, including 10 resistant and 20 sensitive samples. We found miR-19a was significantly up-regulated in resistant group compared with sensitive group (p &lt;0.05). Our study indicated that miR-19a might be a marker to identify cervical cancer patients who are likely to fail concomitant chemoradiotherapy. To verify role of miR-19ain cervical cancer cells is worthy of further investigation.</jats:p> <jats:p>Citation Format: Mei Liu, Lingying Wu, Ningzhi Xu, Jusheng An, Jinlong Hu, Manni Huang, Binbin Tu, Chenfei Hu, Zaozao Wang, Hongxia Zhu. miR-19a modulates chemoradiotherapy resistance in human cervical cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A19.</jats:p> Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer Cancer Prevention Research |
| doi_str_mv |
10.1158/1940-6207.prev-12-a19 |
| facet_avail |
Online Free |
| finc_class_facet |
Medizin |
| format |
ElectronicArticle |
| fullrecord |
blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xOTQwLTYyMDcucHJldi0xMi1hMTk |
| id |
ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xOTQwLTYyMDcucHJldi0xMi1hMTk |
| institution |
DE-Gla1 DE-Zi4 DE-15 DE-Pl11 DE-Rs1 DE-105 DE-14 DE-Ch1 DE-L229 DE-D275 DE-Bn3 DE-Brt1 DE-D161 DE-Zwi2 |
| imprint |
American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv |
American Association for Cancer Research (AACR), 2012 |
| issn |
1940-6207 1940-6215 |
| issn_str_mv |
1940-6207 1940-6215 |
| language |
English |
| mega_collection |
American Association for Cancer Research (AACR) (CrossRef) |
| match_str |
liu2012abstracta19mir19amodulateschemoradiotherapyresistanceinhumancervicalcancer |
| publishDateSort |
2012 |
| publisher |
American Association for Cancer Research (AACR) |
| recordtype |
ai |
| record_format |
ai |
| series |
Cancer Prevention Research |
| source_id |
49 |
| title |
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_unstemmed |
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_full |
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_fullStr |
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_full_unstemmed |
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_short |
Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_sort |
abstract a19: mir-19a modulates chemoradiotherapy resistance in human cervical cancer |
| topic |
Cancer Research Oncology |
| url |
http://dx.doi.org/10.1158/1940-6207.prev-12-a19 |
| publishDate |
2012 |
| physical |
A19-A19 |
| description |
<jats:title>Abstract</jats:title>
<jats:p>Cervical cancer is one of the most common cancers in women worldwide. Advanced uterine cervical squamous cell carcinomasuterine (UCSCC) patients in FIGO stage IIb or IIIb treated with platinum based concomitant chemoradiotherapy. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in UCSCC. In this study, we identified the relationship between miR-19a and sensitivity to concomitant chemoradiotherapy. The UCSCC patients in FIGO stage IIb or IIIb treated with platinum based concurrent chemoradiotherapy at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Patients with progressive disease during first line platinum based chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patients without recurrence or with recurrences beyond 6 months were termed sensitive. We examined the expression level of miR-19a in 30 cervix biopsies samples, including 10 resistant and 20 sensitive samples. We found miR-19a was significantly up-regulated in resistant group compared with sensitive group (p &lt;0.05). Our study indicated that miR-19a might be a marker to identify cervical cancer patients who are likely to fail concomitant chemoradiotherapy. To verify role of miR-19ain cervical cancer cells is worthy of further investigation.</jats:p>
<jats:p>Citation Format: Mei Liu, Lingying Wu, Ningzhi Xu, Jusheng An, Jinlong Hu, Manni Huang, Binbin Tu, Chenfei Hu, Zaozao Wang, Hongxia Zhu. miR-19a modulates chemoradiotherapy resistance in human cervical cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A19.</jats:p> |
| container_issue |
11_Supplement |
| container_start_page |
0 |
| container_title |
Cancer Prevention Research |
| container_volume |
5 |
| format_de105 |
Article, E-Article |
| format_de14 |
Article, E-Article |
| format_de15 |
Article, E-Article |
| format_de520 |
Article, E-Article |
| format_de540 |
Article, E-Article |
| format_dech1 |
Article, E-Article |
| format_ded117 |
Article, E-Article |
| format_degla1 |
E-Article |
| format_del152 |
Buch |
| format_del189 |
Article, E-Article |
| format_dezi4 |
Article |
| format_dezwi2 |
Article, E-Article |
| format_finc |
Article, E-Article |
| format_nrw |
Article, E-Article |
| _version_ |
1792327955427360768 |
| geogr_code |
not assigned |
| last_indexed |
2024-03-01T12:45:37.341Z |
| geogr_code_person |
not assigned |
| openURL |
url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Abstract+A19%3A+miR-19a+modulates+chemoradiotherapy+resistance+in+human+cervical+cancer&rft.date=2012-11-01&genre=article&issn=1940-6215&volume=5&issue=11_Supplement&pages=A19-A19&jtitle=Cancer+Prevention+Research&atitle=Abstract+A19%3A+miR-19a+modulates+chemoradiotherapy+resistance+in+human+cervical+cancer&aulast=Zhu&aufirst=Hongxia&rft_id=info%3Adoi%2F10.1158%2F1940-6207.prev-12-a19&rft.language%5B0%5D=eng |
| SOLR | |
| _version_ | 1792327955427360768 |
| author | Liu, Mei, Wu, Lingying, Xu, Ningzhi, An, Jusheng, Hu, Jinlong, Huang, Manni, Tu, Binbin, Hu, Chenfei, Wang, Zaozao, Zhu, Hongxia |
| author_facet | Liu, Mei, Wu, Lingying, Xu, Ningzhi, An, Jusheng, Hu, Jinlong, Huang, Manni, Tu, Binbin, Hu, Chenfei, Wang, Zaozao, Zhu, Hongxia, Liu, Mei, Wu, Lingying, Xu, Ningzhi, An, Jusheng, Hu, Jinlong, Huang, Manni, Tu, Binbin, Hu, Chenfei, Wang, Zaozao, Zhu, Hongxia |
| author_sort | liu, mei |
| container_issue | 11_Supplement |
| container_start_page | 0 |
| container_title | Cancer Prevention Research |
| container_volume | 5 |
| description | <jats:title>Abstract</jats:title> <jats:p>Cervical cancer is one of the most common cancers in women worldwide. Advanced uterine cervical squamous cell carcinomasuterine (UCSCC) patients in FIGO stage IIb or IIIb treated with platinum based concomitant chemoradiotherapy. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in UCSCC. In this study, we identified the relationship between miR-19a and sensitivity to concomitant chemoradiotherapy. The UCSCC patients in FIGO stage IIb or IIIb treated with platinum based concurrent chemoradiotherapy at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Patients with progressive disease during first line platinum based chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patients without recurrence or with recurrences beyond 6 months were termed sensitive. We examined the expression level of miR-19a in 30 cervix biopsies samples, including 10 resistant and 20 sensitive samples. We found miR-19a was significantly up-regulated in resistant group compared with sensitive group (p &lt;0.05). Our study indicated that miR-19a might be a marker to identify cervical cancer patients who are likely to fail concomitant chemoradiotherapy. To verify role of miR-19ain cervical cancer cells is worthy of further investigation.</jats:p> <jats:p>Citation Format: Mei Liu, Lingying Wu, Ningzhi Xu, Jusheng An, Jinlong Hu, Manni Huang, Binbin Tu, Chenfei Hu, Zaozao Wang, Hongxia Zhu. miR-19a modulates chemoradiotherapy resistance in human cervical cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A19.</jats:p> |
| doi_str_mv | 10.1158/1940-6207.prev-12-a19 |
| facet_avail | Online, Free |
| finc_class_facet | Medizin |
| format | ElectronicArticle |
| format_de105 | Article, E-Article |
| format_de14 | Article, E-Article |
| format_de15 | Article, E-Article |
| format_de520 | Article, E-Article |
| format_de540 | Article, E-Article |
| format_dech1 | Article, E-Article |
| format_ded117 | Article, E-Article |
| format_degla1 | E-Article |
| format_del152 | Buch |
| format_del189 | Article, E-Article |
| format_dezi4 | Article |
| format_dezwi2 | Article, E-Article |
| format_finc | Article, E-Article |
| format_nrw | Article, E-Article |
| geogr_code | not assigned |
| geogr_code_person | not assigned |
| id | ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTE1OC8xOTQwLTYyMDcucHJldi0xMi1hMTk |
| imprint | American Association for Cancer Research (AACR), 2012 |
| imprint_str_mv | American Association for Cancer Research (AACR), 2012 |
| institution | DE-Gla1, DE-Zi4, DE-15, DE-Pl11, DE-Rs1, DE-105, DE-14, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-D161, DE-Zwi2 |
| issn | 1940-6207, 1940-6215 |
| issn_str_mv | 1940-6207, 1940-6215 |
| language | English |
| last_indexed | 2024-03-01T12:45:37.341Z |
| match_str | liu2012abstracta19mir19amodulateschemoradiotherapyresistanceinhumancervicalcancer |
| mega_collection | American Association for Cancer Research (AACR) (CrossRef) |
| physical | A19-A19 |
| publishDate | 2012 |
| publishDateSort | 2012 |
| publisher | American Association for Cancer Research (AACR) |
| record_format | ai |
| recordtype | ai |
| series | Cancer Prevention Research |
| source_id | 49 |
| spelling | Liu, Mei Wu, Lingying Xu, Ningzhi An, Jusheng Hu, Jinlong Huang, Manni Tu, Binbin Hu, Chenfei Wang, Zaozao Zhu, Hongxia 1940-6207 1940-6215 American Association for Cancer Research (AACR) Cancer Research Oncology http://dx.doi.org/10.1158/1940-6207.prev-12-a19 <jats:title>Abstract</jats:title> <jats:p>Cervical cancer is one of the most common cancers in women worldwide. Advanced uterine cervical squamous cell carcinomasuterine (UCSCC) patients in FIGO stage IIb or IIIb treated with platinum based concomitant chemoradiotherapy. However, clinical outcomes vary significantly and are difficult to predict. Tumor intrinsic chemoradiotherapy sensitivity is one of the crucial reasons for concomitant chemoradiotherapy failure in UCSCC. In this study, we identified the relationship between miR-19a and sensitivity to concomitant chemoradiotherapy. The UCSCC patients in FIGO stage IIb or IIIb treated with platinum based concurrent chemoradiotherapy at the Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Patients with progressive disease during first line platinum based chemotherapy or those who suffered recurrent disease within 6 months of completing first line therapy were termed resistant. Patients without recurrence or with recurrences beyond 6 months were termed sensitive. We examined the expression level of miR-19a in 30 cervix biopsies samples, including 10 resistant and 20 sensitive samples. We found miR-19a was significantly up-regulated in resistant group compared with sensitive group (p &lt;0.05). Our study indicated that miR-19a might be a marker to identify cervical cancer patients who are likely to fail concomitant chemoradiotherapy. To verify role of miR-19ain cervical cancer cells is worthy of further investigation.</jats:p> <jats:p>Citation Format: Mei Liu, Lingying Wu, Ningzhi Xu, Jusheng An, Jinlong Hu, Manni Huang, Binbin Tu, Chenfei Hu, Zaozao Wang, Hongxia Zhu. miR-19a modulates chemoradiotherapy resistance in human cervical cancer. [abstract]. In: Proceedings of the Eleventh Annual AACR International Conference on Frontiers in Cancer Prevention Research; 2012 Oct 16-19; Anaheim, CA. Philadelphia (PA): AACR; Cancer Prev Res 2012;5(11 Suppl):Abstract nr A19.</jats:p> Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer Cancer Prevention Research |
| spellingShingle | Liu, Mei, Wu, Lingying, Xu, Ningzhi, An, Jusheng, Hu, Jinlong, Huang, Manni, Tu, Binbin, Hu, Chenfei, Wang, Zaozao, Zhu, Hongxia, Cancer Prevention Research, Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer, Cancer Research, Oncology |
| title | Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_full | Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_fullStr | Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_full_unstemmed | Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_short | Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_sort | abstract a19: mir-19a modulates chemoradiotherapy resistance in human cervical cancer |
| title_unstemmed | Abstract A19: miR-19a modulates chemoradiotherapy resistance in human cervical cancer |
| topic | Cancer Research, Oncology |
| url | http://dx.doi.org/10.1158/1940-6207.prev-12-a19 |